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Introduction
According to a World Health Organization (WHO) report, cardio-
vascular diseases (CVDs) are the number one cause of death globally. 
It was estimated that 17.3 million people died from CVDs in 2008, 
representing 30% of all global deaths. In addition, it is predicted that 
almost 23.6 million people will die from CVDs by 2030 (WHO, 2011). 
The most important risk factors of CVDs are unhealthy diet, physi-
cal inactivity, smoking, and harmful use of alcohol. The effects of 
unhealthy diet and physical inactivity may show up in individuals 
as raised blood pressure, raised blood glucose, raised blood lipids, 
and overweight and obesity. These are called metabolic risk factors. 
Rapid reperfusion of the culprit vessel for salvaging ischemic 
myocardium and optimal medications reduce complications and 
improve survival rate. Although many drugs and medical devices 
have been developed, the incidence of CVDs remains high. More 
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efficacious therapeutic modalities need to be explored by medical 
researchers. Since the discovery of stem cells, a significant amount 
of research and development has emerged to be clinically applied 
for various incurable diseases including CVDs. 
The human heart is a dynamic organ. Traditionally, the myocardi-
um has been considered as terminally differentiated; however, there 
is growing evidence that cardiomyocytes are able to become pro-
liferative when they face substantial damage such as myocardial 
infarction or heart failure.
1)2) In addition to intrinsic repair mecha-
nisms, progenitor/stem cell plasticity has emerged as one of the 
ways to be regenerated.
3)
Stem cells are undifferentiated pluripotent multilineage cells with 
the ability to renew themselves. The sources of stem cells include 
the embryo, fetus, and various parts of adult tissues. Stem cells or 
progenitor cells are classified according to their characteristics in 
Table 1. 
Many clinical trials showed excellent safety and feasibility of adult 
stem cells, but the efficacy of stem cell therapy is not satisfactory to 
improve cardiac function substantially. 
The basic mechanisms of stem cell action on the injured myocar-
dium will not be discussed here. We will focus instead on the current 
status of preclinical/clinical studies regarding therapeutic opportu-
nities.
In this review, we summarize recent results of preclinical/clinical 
trials that have evaluated the safety, feasibility, and efficacy of cell 
therapy in heart disease. Stem Cell Therapy in Myocardial Infarction 72 
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Walking With Animal Study
Direct or indirect transplantation of adult stem cells to damaged 
hearts is emerging as an innovative strategy to ameliorate cardiac 
remodeling and dysfunction after acute myocardial infarction (AMI). 
Potential sources of functional cardiomyocytes has been explor-
ed and utilized for cell therapy to replace injured cardiomyocytes. 
Stem cells are characterized by their ability to self-renew, clone, and 
differentiate into multiple tissues. Adult stem cells are isolated and 
characterized from various sources; peripheral blood,
4) bone marrow 
(BM),
5) adipose tissue,
6) umbilical cord blood,
7) amniotic membrane,
8) 
and dental pulp.
9)
A large number of animal studies have demonstrated that stem 
cells could be engrafted and differentiated within the heart.
3)10-12) In 
preclinical studies, several large-animal species, including swine, 
sheep, and dogs, have been used to investigate the effects of stem 
cell therapy in CVDs models. Stem cells can be delivered to the heart 
by intravenous infusion, direct surgical injection, or catheter-based 
intracoronary infusion. 
Orlic and colleagues first reported the repair of infarct myocardi-
um through transplantation of bone marrow cells (BMCs) in mice.
3) 
Progenitors or stem cells with cardiomyogenic potential were stu-
died both in vitro and in vivo. Experimental data showed the expres-
sion of cardiac markers such as cardiac contractile proteins in stem 
cells in transplanted myocardium. However, they were rarely found. 
One of the popular strategies to increase the cardiomyogenesis 
of stem cells is the stimulation of stem cells with an anticancer drug, 
5-azacytidine, which is a nonspecific deoxyribonucleic acid methyla-
tion inhibitor. Transient stimulation with 5-azacyticine for one day 
substantially increased cardiac protein expression in BM-derived 
mesenchymal stem cells (MSCs) and sca-1-positive adult cardiac 
stem cells with spontaneous beating on culture system.
13) 
Table 1. Major cell types with potential for cardiac cell therapy
Cell type Source Advantages Limitations
Cardiac stem 
  cells
Allogenic fetal, neonatal, 
  or adult heart
Recognition of myocardial growth factors and  
  recruitment to myocardium are likely faster and  
  more efficient than other cell types
  In vivo electrical coupling of transplanted cells to 
  existing myocardium has been demonstrated
Poor cell growth in vitro
Transplanted cells are very sensitive to  
  ischemic insult and apoptotic cell death
Availability from either fetal (F), neonatal (N), 
  or adult sources is low at present; likely 
  immune rejection; F and N cells pose ethical 
  difficulties
Skeletal  
  myoblast
Autologous skeletal 
  muscle biopsy
Cells proliferate in vitro (allowing for autologous 
  transplant)
Ischemia resistant
Transplanted myoblasts can differentiate into  
  slow-twitch myocytes (similar to cardiomyocytes)  
  enabling cellular cardiomyoplasty
Reduces progressive ventricular dilatation and  
  improves cardiac function
Can use adult cells
Likely do not develop new cardiomyocytes  
  in vivo
Electrical coupling to surrounding  
  myocardial cells is unclear 
Long-term stability of differentiated  
  phenotype unknown
Adult bone  
  marrow 
  stem cells
Autologous bone marrow
  stromal cells 
  (mesenchymal); bone
  marrow (endothelial 
  progenitor cells)
Pluripotent stem cells can develop into cardiomyocytes
Stem cells are easy to isolate and grow well in culture
Neovascularization can occur at the site of myocardial 
  scar reducing ischemia
Transdifferentiation of cells into cardiomyocytes in vivo
  has been shown
Can be derived from autologous source; no  
  immune-suppression treatment
Can improve myocardial contractile function
New program of cell differentiation  
  is required
Efficiency of the differentiation into adult  
  cardiomyocytes appears limited
Signaling, stability, and regulation  
  of differentiation unknown
Embryonic 
  stem cells
Allogenic blastocyst 
  (inner mass)
Easy propagation and well-defined cardiomyocyte  
  differentiation process
In vivo electrical coupling of transplanted cells to 
  existing myocardial cells
Pluripotent cells
Potential for tumor formation and immune 
  rejection (allogenic)
Incomplete response to physiological stimuli
Legal and ethical issues
Donor availability
Marin-Garcia M. Heart failure: bench to bedside. New York: Springer; 2010Yong Sook Kim, et al. 73
http://dx.doi.org/10.4070/kcj.2012.42.2.71 www.e-kcj.org
To prove functional stem cell therapy, a small animal model has 
widely been used. Myocardial infarction was experimentally in-
duced by surgical ligation of the coronary artery such as left ante-
rior descending artery in mice or rats, sometimes with reperfusion. 
Various stem cell types, transplantation route, cell number, and tr-
ansplantation timing have been studied in these small animal mod-
els. Many studies are reported that stem cell therapy is safe, feasible, 
and promising for the cure of MI. Histological data has revealed 
that the injected stem cells can survive in ischemic myocardium 
that participated in neovascularization and cardiomyogenesis. Scar 
size, cardiac remodeling, fibrosis, and inflammation were much more 
effectively improved. Cardiac function was also substantially im-
proved after stem cell therapy. Based on these fantastic results of 
animal studies, many clinical studies were designed and initiated to 
Table 2. Summary of results from mesenchymal stem cell therapy cases in the swine model
Study Cell type/delivery route MI induction Time of delivery Results F/U F/U measurement
Shake  
et al.
36)
Autologous BM-MSC, 
10
7 cells/direct injection
60-minute LAD  
occlusion
2 week Systolic wall  
thickening ↑
4 week  Sonomicrometry 
crystals
Amado  
et al.
37)
Intramyocardial injections  
of either allogeneic porcine  
MSCs (2.0×10
8 cells)
60-minute LAD  
occlusion
3 day  Diastolic function ↑, 
mechanoenergetics ↑, 
EF ↑, EDV ↓
CMR
Lim et al.
16) Allogeneic BM-MSC,  
1×10
7cells, IC
30-minute LAD  
occlusion
3 day EF ↑, infarct area ↓, 
viable myocardium ↑
SPECT
Price  
et al.
38)
Allogeneic, 3.2±0.4×10
8
cells, IV (internal jugular vein)
60-minute LAD  
occlusion
30 minute EF ↑, hypertrophy ↓ 12 week Echocardiography
Freyman  
et al.
39)
Allogeneic BM-MSC, 5×10
7 cells, 
IV, IC, EC
60-minute LAD  
occlusion
1 5 minute Engraftment within infarct  
myocardium ↑: IC>EC>IV
Remote organ engraftment:  
EC<IC, IV
2 week FISH staining
Feygin  
et al.
40)
Autologous BM-MSC, 5×10
7 cells, 
direct intramyocardial injection
LAD ligation after  
left thoracotomy
Right after MI Contractile performance ↑, 
wall stress ↓
12 week CMR
Schuleri  
et al.
41)
Allogeneic BM-MSC,  
intramyocardial injection
60-minute LAD  
occlusion
3 day Cardiac performance ↑, 
infarct size ↓
8 week CMR
Hashemi  
et al.
42)
Allogeneic BM-MSC, 2.4×10
7, 
2.4×10
8, 4.4×10
8 cells, 
endomyocardial delivery
60-minute LAD  
occlusion
3 day Safe and produced a local  
but not a functional effect
12 week CMR
Gyöngyösi  
et al.
43)
Allogeneic BM-MSC, 7.2×10
6 cells, 
intramyocardial injection
60-minute LAD  
occlusion
16 day The persistence of viable MSC  
at 10 days after delivery
10 day CMT, PET-CT
Wolf  
et al.
44)
Autologous or allogeneic BM-MSC,  
1×10
3 to 1×10
6/kg, iv (ear vein)
LAD ligation after 
lateral thoracotomy
2 day EF ↑, infarct size ↓ 4 week Echocardiography
Moscoso  
et al.
45)
5-azacytidine-treated BM-MSC, 
31.7±11.61×10
6, IC, IM, EC
120-minute LAD 
occlusion
1 month Engraftment rate: IC<IM, EC 1 month Postmortem section
Ly et al.
46) MPC, MSC, MNC, PBMNC,  
2×10
7 cells, IC
60-minute LAD  
occlusion
3-4 day Retention rate: MSC ↑   1 hour Near-infrared 
fluorescence
Schuleri  
et al.
47)
Autologous BM-MSC, 2×10
7 or 
2×10
8, surgical injection
120-minute LAD 
occlusion
12 week Regional contractility ↑, 
infarct size ↓
12 week CMR
Dubois  
et al.
48)
Autologous EPC (34±22×10
6), 
allogeneic MSC (10±2×10
6), IC
90-minute occlusion  
of proximal  
circumflex artery
1 week EPC: infarct size ↓, 
vascular density ↑,
MSC: EF ↑
7 week CMR
Ellison  
et al.
49)
IGF-1 & HGF administration 
to activate endogenous  
cardiac stem cells
60-minute LAD  
occlusion
30 minute  Fibrosis ↓, hypertrophy ↓, 
infarct size ↓, 
cardiac function ↑
8 week CMR
BM: bone marrow, CMR: cardiac magnetic resonance imaging, EDV: end-diastolic volume, EC: endocardial injection, EF: ejection fraction, EPC: endothelial 
progenitor cells, HGF: hepatocyte growth factor, IC: intracoronary infusion, IGF-1: insulin like growth factor-1, IM: intramyocardial injection, LAD: left an-
terior descending artery, MNC: mononuclear cells, MPC: multipotent progenitor cells, MSC: mesenchymal stem cells, PBMNC: peripheral blood-derived 
mononuclear cells, PET-CT: positron emission tomography-computed tomography, SPECT: single-photon emission computed tomography, MI: myocardial 
infarction, IV: intravenous, FISH: fluorescence in situ hybridization, F/U: follow-upStem Cell Therapy in Myocardial Infarction 74 
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transfer stem cell therapy to the bedside all over the world.
Various stem cells or progenitor cells have been introduced for 
cardiac repair in the last few years, although many past and ongoing 
clinical trials use predominantly adult autologous BM-derived cells. 
The use of BMCs in CVDs has the advantage that BM can be easily 
accessed, and isolated cells can be expanded for autologous applic-
ation.
Experimental studies of cell priming revealed that it improved cell 
survival, retention, integration, and differentiation.
12)14)15) In addition, 
genetic modification of stem cells before application with the pro-
survival gene Akt,
16) vascular endothelial growth factor,
17) or fibro-
blast growth factor 2
18) promoted therapeutic efficacy.
Table 2 shows summarized results of MSCs therapy in porcine 
AMI model. The anatomy and physiology of the porcine heart is well 
known to be similar to a human heart, and it is considered that the 
porcine MI model is the best model for CVDs research. Cell number, 
delivery procedure, and surgical techniques in the porcine model are 
also similar to the clinical setting, and more realistic implications 
could be provided compared with a small animal model.
Running With Clinical Study
In AMI, cardiac muscle is damaged to become dysfunctional. After 
successful percutaneous coronary intervention (PCI) and coronary 
artery bypass graft surgery with optimal medications, cardiac func-
tion is restored only to a limited degree {3-4% improvement in left 
ventricular ejection fraction (LVEF)} which may result in cardiac re-
modeling in approximately 60% of the patients with myocardial in-
farction.
19)20) 
Many clinical studies have proceeded for proving their safety and 
efficacy to reach a final goal “new therapy”. Regarding cell type, most 
clinical trials have used unfractionated BMCs as the delivery prod-
uct, postulating that stem/progenitor cells are the biologically ap-
plicable therapeutic agents. The most widely applicable technique for 
stem cell delivery is intracoronary infusion from a clinical standpoint.
The first human clinical trial of stem cell trial was intracoronary in-
fusion of autologous BM unfractionated mononuclear cells to AMI 
patient.
21) Subsequent clinical studies of stem cells for AMI were 
then initiated. 
A variety of studies have demonstrated significant improvement 
of ventricular performance after stem cell therapy in AMI, resulting 
in an increase in LVEF and decrease in infarct size. In most cases, 
stem cell transplantation was performed in a time frame of 12 hours 
to several days after MI. Although there is large variability of hemo-
dynamic data after cell therapy, there is moderate improvement of 
cardiac performance by stem cell therapy that is more quantita-
tively effective than therapeutic interventions and pharmacothera-
py.
22) Thus, autologous stem cell therapy represents an innovative 
and effective procedure for regeneration of impaired hearts in the 
early phase after the infarct. 
As seen in Table 3, most recent clinical trials utilized BM-derived 
mononuclear cells isolated from patients after PCI. BM has been 
considered the safest source for autologous transplantation of stem 
cells, usually mononuclear cells, in clinical trials. For now the most 
widely used clinically approved source for stem cell therapy is au-
tologous stem cells from BM (www.clinicaltrials.gov). 
In addition to BM-mononuclear cells, MSCs are now actively un-
der investigation for cardiac repair. BM contains a population of he-
matopoietic stem cells and a rare population of plastic-adherent 
stromal cells (1 in 10000 nucleated cells in BM).
23) 
These plastic adherent cells are MSCs capable of forming single-
cell colonies, expansion in culture, differentiation into osteoblasts, 
chondrocytes, and adipocytes.
24)25) MSCs were shown to be differ-
entiated into a myogenic phenotype.
13) Animal studies demonstrated 
that human MSCs could be transdifferentiated into endoderm-de-
rived cells
10) in injected myocardium, and coculture of MSC with ven-
tricular myocytes induced transdifferentiation into a cardiomyo-
cyte phenotype in vitro.
26) Large-animal preclinical studies of MSCs 
administration in post-MI heart demonstrated the ability of MSCs 
to engraft, differentiate, and produce substantial functional recov-
ery.
12)16)27)28) 
The therapeutic effect of MSC on AMI has been reported in four 
clinical trials. Chen et al.
29) infused autologous MSC by intracoro-
nary route and demonstrated regional wall motion and global LVEF 
were improved after six months of cell therapy. At that time, Vulliet 
et al.
30) reported that a microinfarction occurred after intracoronary 
infusion of MSCs in a dog MI model. A Prochymal trial
31) was de-
signed to evaluate the safety of intravenous application of alloge-
neic BM-derived MSCs to AMI patients. According to animal studies, 
a large proportion of infused cells were trapped in the lungs after ad-
ministration, raising potential concerns regarding compromised pul-
monary function.
32) The results of the Prochymal trial did not show 
any evidence of a pulmonary safety risk after infusion of allogeneic 
human (h)BM-MSCs. Instead, those data revealed improved pulmo-
nary function in the MSC-treated patients, compared with baseline 
status. The rate of arrhythmia event was 4-fold lower in the hMSCs 
group than in the placebo group (8.8% vs. 36.8%, p=0.025). In isch-
emic cardiomyopathy, transendocardial injection of autologous BM-
derived progenitor cells including mononuclear cells or MSCs pro-
duced functional recovery in scarred myocardium and reversed 
remodeling of the LV chamber.
33) Unfortunately, however, they did 
not determine superiority between mononuclear cells and MSCs. 
Without the placebo control group, data from only 4 patients in 
each group were analyzed. The transendocardial autologous cells Yong Sook Kim, et al. 75
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Table 3. Summary of recent stem cell therapy trials in myocardial infarction (and heart failure)
Trial Cell 
Time of  
delivery  
(days after MI)
Results
F/U
(months)
Patients (age)
van Ramshorst  
et al.
52)
Autologous BM-MNC, 
1×10
8 cells, 
intramyocardial  
injection
Chronic  
myocardial 
ischemia
Modest improvement of summed stress  
score, LVEF in BMC group at 3 month,  
increase of quality of life at 6 month 
3, 6  Placebo 25 (62),  
cell 25 (64)
Meyer et al.,  
BOOST trial
53)
Autologous BMC, 
24.6×10
8, IC
5 days EF decrease by 3.3±9.5% in control, 
2.5±11.9% in BMC
Not promote a sustained improvement of EF
61 Control 30 (59.2),  
BMC 30 (53.4)
Tendera et al.,  
REGENT trial
54)
BM-MNC (1.78×10
8),
CD34+ (1.9×10
6), 
IC
PCI after  
12 hour MI  
onset 
EF: 39 to 39 in control, 37 to 40 in MNC,  
35 to 38 in CD34+ group
6 Control 40 (59),  
non selected MNC  
80 (55), selected MNC  
80 (58)
Beitnes et al.,  
ASTAMI trial
55)
BMC, 7×10
7, IC 4-7 day Safe in the long-term, small ↑ in exercise time, 
no other effects in BMC group, echo con  
46.9 to 46.8 BMC 45.7 to 47.5 MRI con  
53.5 to 55.2 BMC 54.8 to 54.9
36 Control 50 (56.7),  
BMC 50 (58.1)
Hare et al.,  
Prochymal
31)
Allogeneic BM-MSC,  
0.5, 1.6, 5×10
6 
cells/kg, iv
1-10 day EF ↑ 12 Placebo 21 (55.1),  
hMSC 39 (59.0)
Assmus et al.,  
REPAIE-AMI
56)
Auto BMC,  
236±174×10
6, IC
3-7 day after  
reperfusion
Still safe 24 Placebo 103 (57),  
BMC 101 (55) 
Grajek et al.
57) BMC, 2.34±1.2×10
9,
 IC
4-6 day after  
PCI
EF, LVEDV, LVESV, spiroergometric stress  
test: no difference
6, 12 Control 14 (50.9),  
BMC 31 (49.9)
Arnold et al.,  
TECAM study
58)
BM-MNC,  
97.6±61.4×10
6, IC
STEMI, <9±3 
day of  
reperfusion
No difference in minimum lumen diameter,  
stenosis, changes in the contralateral  
artery, plaque volume
9 Control 37 (59.8),  
TECAM 37 (58.6)
Strauer et al.,  
STAR-heart study
59)
BMC, 6.6±3.3×10
7, IC Chronic HF EF  
<35% (mean  
post MI interval: 
8.5 year)
Haemodynamics, exercise capacity, oxygen  
uptake, LV contractility, long-term  
mortality ↑ in BMC group
3, 12, 60 Control 200 (60),  
stem cell 191 (59)
Seth et al.,  
ABCD trial-long  
term FU
60)
BM-MNC, IC  
(with coronary  
sinus blockage)
Dilated  
cardiomyopathy 
EF <35%
EF 5.4% ↑ (20±7.4 to 25±12), ESV ↓ (144 mL 
to 116 mL), EDV: no change at 6 mo
EF ↑ (22.5±8.3 to 28.4±11.8), ESV ↓ at 36 mo
36 Control 20 (45),  
stem cell 24 (49)
Traverse et al.
61) Auto BMC 1×10
8, IC STEMI EF 49±9.5 to 55.2±9.8, placebo EF 48.6±8.5 
to 57±13.4, LVEDP ↓
6 Placebo 10 (57.5),  
BMC 30 (52.5)
Williams et al.
33) Transendocardial,  
intramyocardial  
injection of auto BM-MNC  
(1 or 2×10
8),
or MSC (1 or 2×10
8)
Ischemic  
cardiomyopathy
EDV (208.7±20.4 to 167.4±7.32 mL), 
infarct size ↓, regional function ↑ at 3 mo, 
changes in chamber dimensions  
not diff at 6 mo
12 Stem cell 8 (57.2)
Santoso et al.
62) G-CSF (10 mg/kg/day)  
5 days then PBSC 
harvested, recombinant 
erythropoietin (SQ inj) 
+PBSC 15 - 25×10
6, IC
15 day after PCI  
with DES  
within 15 day 
after onset
No diff in LVEDV, LVESV at 3 mo,  
but ↑ at 1 year
12-30 18 (55.4)
Mansour et al.,  
COMPARE-AMI
63)
CD133+HSC,  
1×10
7, IC
3-7 day after  
PCI
Safe, EF 41.2±1 at base, 51.1±2.5 at 4 mo, 
52.3±2 at 12 mo
12 Placebo 20,  
cell 20 (52.2)Stem Cell Therapy in Myocardial Infarction 76 
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in an ischemic heart failure trial (TAC-HFT) and Percutaneous Stem 
Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) tri-
als
34) are in progress to intensify those limitations (www.clinicaltri-
als.gov). TAC-HFT is designed for comparing BM-MSCs versus mo-
nonuclear cells, and POSEIDON is comparing the effects of allo-
geneic versus autologous MSC therapy in ischemic cardiomyopathy 
patients.
The delivery of MultiStem, an allogeneic BM-derived stem cell 
produced by Athersys, Inc. (Cleveland, OH, USA), to AMI patients has 
proved to be safe and well tolerated.
35) They showed MultiStem 
delivered via transarterial adventitia using a microsyringe catheter 
was safe with improvement of cardiac function in a dose-dependent 
manner.
Although the exact mechanism of MSC effects is still unresolved, 
accumulating results of large animal studies and clinical studies 
have shown that MSC-based therapy for cardiac repair is safe and pro-
vides substantial improvement in cardiac structure and function.
Looking Back With Consideration
The therapeutic effect of stem cell therapy on heart disease has 
been shown by experimental studies using small animal models. Re-
sults have been reported as extraordinarily promising with experi-
mental results such as cardiomyogenesis, neovascularization, and 
paracrine effect on injured myocardium.  Now we are facing chal-
lenges for bringing stem cells to clinically applicable therapeutics. 
Intracoronary transfer of autologous BMCs after optimum reperfu-
sion therapy does not dramatically augment recovery of global LV 
function in patients, but could favorably affect cardiac remodeling 
after MI. Mixed results have been reported in clinical trials of stem 
cell administered patients after AMI with minimal improvement of 
ejection fraction or only a transient clinical benefit.
The different outcomes were attributed to differences in cell prep-
arations, timing and method of cell administration, choice of end-
points, and characteristics of patients. Some studies failed to deter-
Table 3. Continued
Trial Cell 
Time of  
delivery  
(days after MI)
Results
F/U
(months)
Patients (age)
Hirsch et al.,  
HEBE trial
64)
BM 296±164×10
6 
or peripheral MNC  
287±137×10
6
IC 4-7 day  
after MI
No difference (control 42.4±18.7%, 
BM 38.6±24.7, PB 36.8±20.9)
4 Control 65 (55),  
BMC 69 (56),  
PBMC 66 (57)
Penn et al.
65) Allo MultiStem to the  
adventitia of the  
infarct-related vessel,  
2×10
7, 6×10
7, 1×10
8
2-5 day  
after AMI
EF: 20 M (4.1% ↑), 50 M (8.7% ↑), 
100 M (no change) 
LV stroke volume: control (-4.3 mL),  
20 M (-3.6 mL), 50 M (+14.6 mL),  
100 M (+7.9 mL) 
4 Control 6 (53), MultiStem 
20 million n=6 (64),  
60 million n=7 (54),  
100 million n=6 (53)
Bolli et al., 
SCIPIO
66)
CSCs, IC, 1 million  
(n=15), 0.5 million (n=1)
EF <40%,  
CABG,  
ischemic  
cardiomyopathy
EF 35.9% to 39.2% (4 mo),  
to 42.5% (12 mo), infarct size 32.6  
to 24.8 (4 mo), to 22.8 (12 mo) 
12 Control 7 (57.3),  
treatment 16 (56.0)
Moreira  
et al.
67)
BM-MNC 1×10
8, anterograde
intra-arterial coronary (IAC)  
or retrograde intravenous  
coronary (IVC)
24 hour <MI,  
infract size  
>10%
Comparison of cell retention:  
IAC (16.14%), IVC (4.62%) at 4 hour,  
IAC (10.29%), IVC (3.13%) at 24 hour
24 hour Control 6 (57.2),  
IAC 14 (59.7),  
IVC 10 (53.6)
Solheim et al.
68) BM-MNC 68×10
8, IC 6 day after the STEMI No changes in prothrombotic markers 3 Control 50,  
cell 50 (57.4)
Roncalli et al., 
BONAMI trial
69)
Auto BMC, IC 9.3 day after  
STEMI
Myocardial viability 16% (control), 
 34% (BMC), active significant  
adverse role of smoking
3 Control 49 (55),  
BMC 52 (56)
Ahmadi et al.
70) BM-CD133+BMC, 1.77×10
6±
1.14×10
6 CD133+cells, 
intramyocardial transplantation
Candidate of CABG 
after MI
Safe, no benefit 60 Control 5, BMC 13
BM: bone marrow, EDV: end-diastolic volume, EF: ejection fraction, IC: intracoronary infusion, MNC: mononuclear cells, MSC: mesenchymal stem cells, 
BMC: bone marrow cell, MI: myocardial infarction, PCI: percutaneous coronary intervention, STEMI: ST segment elevation myocardial infarction, HF: heart 
failure, DES: drug-eluting stent, LVEF: left ventricular ejection fraction, LVEDV: left ventricular end diastolic volume, LVESV: left ventricular end systolic vol-
ume, ESV: end-systolic volume, AMI: acute myocardial infarction, CABG: coronary artery bypass graft, PB: peripheral blood, LV: left ventricle, G-CSF: granu-
locyte colony stimulating factor, PBSC: peripheral blood stem cell, LVEDP: left ventricular end diastolic pressure, CSC: cardiac stem cellYong Sook Kim, et al. 77
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mine persistent clinical benefits after stem cell application (Table 3). 
Arrhythmias have been reported to be associated with intramyo-
cardial rather than intracoronary injection of stem cells in the early 
clinical studies; intramyocardial injection could be responsible for 
arrhythmogenesis. In addition, local injection induces a highly un-
even distribution of cells, at least early after injection, which in-
creases electrophysiological heterogeneity. Although recent avail-
able results of clinical experience
35)36) so far suggest that proarrhy-
thmic effects may be transient, cardiac arrhythmia occurs unpre-
dictably, and long-term follow-up studies would be essential to un-
derstand the arrhythmogenesis induced by stem cell transplantation.
The most effective and safe cell type for myocardial repair and the 
clinical significance of cell therapy-induced arrhythmias will be 
determined in future pre-clinical and clinical studies. 
There was a case report about fatal events after autologous he-
matopoietic stem cell application in a lupus nephritis patient.
37) After 
direct renal injection of stem cells isolated from peripheral blood, 
masses at the sites of injection were developed with hematuria. 
Pathologic analysis revealed the masses were angiomyeloprolifera-
tive lesions and suggested to be a possible complication of stem cell 
therapy. There was no way to find out the detailed cause of death in 
those cases, but stem cell transplantation could be a causative event.
The ultimate goal of cell therapy is the regeneration of lost cardiac 
muscle along with the reversal of adverse remodeling. Despite grow-
ing clinical experience, the absence of standardized clinical end point 
in human trials has left us with fundamental questions. Issues to be 
addressed in the future include determining the ideal cell type, the 
cell number to be delivered, optimal cell isolation method, efficient 
cell storage, and optimal time of administration to improve the ef-
ficacy of the therapy. After that, more realistic and optimized condi-
tions of stem cell therapy will be applied to patients suffered from 
CVDs with guaranteed safety.
The risk of exposing patients to possible adverse outcomes of cell 
therapy must be seriously considered before clinical application. 
The argument that clinical trials should be delayed till mechanisms 
are perfectly understood will deprive a large number of patients from 
therapeutic chances that may bring them clinical recovery. Stem 
cell therapy is a novel and innovative approach to cardiac therapeu-
tics which has been achieved by numerous preclinical and early clini-
cal studies showing safety, feasibility, and early efficacy.
Conclusion
Recent evidence from studies in animals and humans demon-
strates the important roles of stem cells in CVDs. In this review, re-
ports of recent clinical trials of stem cell therapy for myocardial in-
farction are summarized and some important considerations are 
suggested for further application. For now, the challenge is to im-
proveme the scientific concept to clinical setting with current treat-
ment modalities.
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